Luis A. Diaz, Jr, MD, associate professor of oncology, Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, discovered that patients with high mutational burden with mismatched repair responded well to checkpoint inhibition of PD1.
uis A. Diaz, Jr, MD, associate professor of oncology, Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, discovered that patients with high mutational burden with mismatched repair responded well to checkpoint inhibition of PD1. For colon cancer and perhaps for additional cancers such as pancreatic, lung, and ovarian, Dr Diaz predicts that mismatched repair testing will change the course of cancer treatment in the coming years.
L
“My suspicion is that this will become standard of care in the near future for colon cancer. And that will demand that mismatched repair testing be a part of the standard of care for those patients,” Dr Diaz said. “And I suspect that up front, when you get diagnosed with advanced colon cancer, you’re going to get mismatched repair testing.”
Johns Hopkins Sidney Kimmel Comprehensive Cancer Center is now in collaboration with Merck, which Dr Diaz said is in the beginning stages of opening 2 new studies focused on patients who failed all therapy and on patients who are newly diagnosed in an effort to compare which standard of care works more effectively.
Standard Criteria for Loss of Ambulation Needed in DMD
April 19th 2024A recent study suggests the differences between ambulation definitions for patients with Duchenne muscular dystrophy (DMD) can impact the identification of ambulant vs nonambulant individuals, and standard criteria across settings are needed.
Read More
Early Involvement Critical in Treating Immunotherapy-Induced Overlap Syndrome
April 19th 2024A series of case studies reveals the importance of early diagnosis and involvement of special teams of clinicians when dealing with potential cases of overlap syndrome, which encompasses myocarditis, myasthenia gravis, and immune checkpoint inhibitor–related myositis.
Read More
Oncology Onward: A Conversation With Penn Medicine's Dr Justin Bekelman
December 19th 2023Justin Bekelman, MD, director of the Penn Center for Cancer Care Innovation, sat with our hosts Emeline Aviki, MD, MBA, and Stephen Schleicher, MD, MBA, for our final episode of 2023 to discuss the importance of collaboration between academic medicine and community oncology and testing innovative cancer care delivery in these settings.
Listen
Government agencies have created an online portal for the public to report potential anticompetitive practices in health care; there are changes coming to the “boxed warning” section for chimeric antigen receptor T-cell therapies (CAR T) to highlight T-cell blood cancer risk; questions about the safety of obesity medications during pregnancy have arisen in women on them who previously struggled with fertility issues.
Read More